Literature DB >> 3972966

Decreased urinary C19 and C21 steroid 5 alpha-metabolites in parents of male pseudohermaphrodites with 5 alpha-reductase deficiency: detection of carriers.

J Imperato-McGinley, R E Peterson, T Gautier, A Arthur, C Shackleton.   

Abstract

The urinary 5 beta/5 alpha ring A-reduced metabolites of C19 and C21 steroids from obligate carrier parents of male pseudohermaphrodites with 5 alpha-reductase deficiency were analyzed by gas chromatography. Etiocholanolone/androsterone, 11 beta-hydroxyetiocholanolone/11 beta-hydroxyandrosterone, tetrahydrocortisol/allotetrahydrocortisol, and tetrahydrocorticosterone/allotetrahydrocorticosterone were the paired 5 beta/5 alpha-metabolite ratios measured. Increased mean 5 beta/5 alpha ratios were found for all paired metabolites compared to mean ratios in normal subjects. In men, the highest index of discrimination of the carrier state was the tetrahydrocorticosterone/allotetrahydrocorticosterone ratio, while in women, the etiocholanolone/androsterone ratio was more diagnostic. In obligate carrier men, plasma testosterone, dihydrotestosterone, androstenedione, and 17 alpha-hydroxyprogesterone levels were normal, as were testosterone/dihydrotestosterone ratios. These studies demonstrate a generalized defect in 5 alpha-reductase activity involving C19 and C21 steroid metabolism in obligate carrier parents and provide further confirmation of an autosomal recessive mode of inheritance in this condition. The data from parents of sporadic cases of male pseudohermaphrodites with primary 5 alpha-reductase deficiency suggest that there is a carrier rate within the general population, although the exact frequency remains unknown.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3972966     DOI: 10.1210/jcem-60-3-553

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

2.  Male pseudohermaphroditism due to 5 alpha-reductase-2 deficiency in an Arab kindred.

Authors:  H M al-Attia
Journal:  Postgrad Med J       Date:  1997-12       Impact factor: 2.401

3.  Unexpected virilization in male mice lacking steroid 5 alpha-reductase enzymes.

Authors:  M S Mahendroo; K M Cala; D L Hess; D W Russell
Journal:  Endocrinology       Date:  2001-11       Impact factor: 4.736

4.  Male pseudohermaphroditism due to primary 5 alpha-reductase deficiency: variation in gender identity reversal in seven Mexican patients from five different pedigrees.

Authors:  J P Méndez; A Ulloa-Aguirre; J Imperato-McGinley; A Brugmann; M Delfin; B Chávez; C Shackleton; S Kofman-Alfaro; G Pérez-Palacios
Journal:  J Endocrinol Invest       Date:  1995-03       Impact factor: 4.256

5.  Male pseudohermaphroditism due to 5 alpha-reductase deficiency in a Swedish family.

Authors:  S A Ivarsson; M D Nielsen; T Lindberg
Journal:  Eur J Pediatr       Date:  1988-06       Impact factor: 3.183

6.  Accuracy of Urinary Etiocholanolone/Androsterone Ratio as Alternative to Serum Testosterone/Dihydrotestosterone Ratio for Diagnosis of 5 Alpha-reductase Type 2 Deficiency Patients and Carriers in Indonesia.

Authors:  Nanis Sacharina Marzuki; Firman Pratama Idris; Hannie Kartapradja; Shirley Renata; Alida Harahap; Jose Rizal Latief Batubara
Journal:  Int J Endocrinol Metab       Date:  2021-04-18

7.  Effects of mitotane treatment on human steroid metabolism: implications for patient management.

Authors:  L Ghataore; I Chakraborti; S J Aylwin; K-M Schulte; D Dworakowska; P Coskeran; N F Taylor
Journal:  Endocr Connect       Date:  2012-07-21       Impact factor: 3.335

8.  Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride.

Authors:  Tina Kiguradze; William H Temps; Steven M Belknap; Paul R Yarnold; John Cashy; Robert E Brannigan; Beatrice Nardone; Giuseppe Micali; Dennis Paul West
Journal:  PeerJ       Date:  2017-03-09       Impact factor: 2.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.